Surgery for renal cell carcinoma metastases

Current Opinion in Urology

Volumn 20, Issue 5, 2010, Pages 375-381

  Breau, Rodney H ^a   Blute, Michael L ^a  

^a MAYO CLINIC   (United States)

Author keywords

metastases; renal cell carcinoma; survival

Indexed keywords

SORAFENIB; SUNITINIB;

ABSCESS; ADJUVANT THERAPY; ADRENAL METASTASIS; BONE METASTASIS; BRAIN METASTASIS; BRAIN RADIATION; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CYTOREDUCTIVE SURGERY; DISTANT METASTASIS; HEART ARRHYTHMIA; HEART INFARCTION; HUMAN; KIDNEY CARCINOMA; LIVER METASTASIS; LIVER RESECTION; LUNG EMBOLISM; LUNG METASTASIS; LUNG RESECTION; LYMPH NODE METASTASIS; LYMPHADENECTOMY; METASTASECTOMY; METASTASIS; MOLECULARLY TARGETED THERAPY; MULTIMODALITY CANCER THERAPY; NEPHRECTOMY; PANCREAS METASTASIS; PNEUMONIA; POSTOPERATIVE HEMORRHAGE; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; REVIEW; STEREOTACTIC RADIOSURGERY; SURVIVAL TIME; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR ABLATION; VEIN THROMBOSIS; WOUND DEHISCENCE;

CARCINOMA, RENAL CELL; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; HUMANS; KIDNEY NEOPLASMS; NEOADJUVANT THERAPY; NEPHRECTOMY; RADIOTHERAPY, ADJUVANT; TIME FACTORS; TREATMENT OUTCOME;

EID: 77955472908     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOU.0b013e32833c7ada     Document Type: Review

References (47)

1. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med 1996; 335:865-875.
2. Motzer RJ, Mazumdar M, Bacik J, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999; 17:2530-2540.
3. Escudier B, Eisen T, Stadler WM, et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009; 27:3312-3318. This is the final outcome publication of a randomized controlled trial of Sorafenib in patients with metastatic renal cell carcinoma who have failed immunotherapy.
4. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27:3584-3590. This is the final outcome publication of a landmark randomized controlled trial of sunitinib versus interferon-a in patients with metastatic renal cell carcinoma.
5. Flanigan RC, Mickisch G, Sylvester R, Tangen C, Van Poppel H, Crawford ED. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 2004; 171:1071-1076.
6. Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renalcell cancer. N Engl J Med 2001; 345:1655-1659.
7. Mickisch GH, Garin A, van Poppel H, et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001; 358:966-970.
8. Marcus SG, Choyke PL, Reiter R, et al. Regression of metastatic renal cell carcinoma after cytoreductive nephrectomy. J Urol 1993; 150 (2 Pt 1):463-466.
9. Gleave ME, Elhilali M, Fradet Y, et al. Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group. N Engl J Med 1998; 338:1265-1271.
10. Leibovich BC, Cheville JC, Lohse CM, et al. A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. J Urol 2005; 174:1759-1763; discussion 1763.
11. Naito S, Yamamoto N, Takayama T, et al. Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1463 patients. Eur Urol 2009; 57:317-325. This is a large observational study from Japan that reveals improved survival in patients treated with metastasectomy. Inadequate detail was available to characterize the effect of prognostic factors such as complete metastasectomy.
12. Vogl UM, Zehetgruber H, Dominkus M, et al. Prognostic factors in metastatic renal cell carcinoma: metastasectomy as independent prognostic variable. Br J Cancer 2006; 95:691-698.
13. Eggener SE, Yossepowitch O, Kundu S, et al. Risk score and metastasectomy independently impact prognosis of patients with recurrent renal cell carcinoma. J Urol 2008; 180:873-878; discussion 878.
14. Kavolius JP, Mastorakos DP, Pavlovich C, et al. Resection of metastatic renal cell carcinoma. J Clin Oncol 1998; 16:2261-2266.
15. van der Poel HG, Roukema JA, Horenblas S, et al. Metastasectomy in renal cell carcinoma: a multicenter retrospective analysis. Eur Urol 1999; 35:197-203.
16. Daliani DD, Tannir NM, Papandreou CN, et al. Prospective assessment of systemic therapy followed by surgical removal of metastases in selected patients with renal cell carcinoma. BJU Int 2009; 104:456-460.
17. Kwak C, Park YH, Jeong CW, Lee SE, Ku JH. No role of adjuvant systemic therapy after complete metastasectomy in metastatic renal cell carcinoma? Urol Oncol 2007; 25:310-316.
18. Kierney PC, van Heerden JA, Segura JW, Weaver AL. Surgeon's role in the management of solitary renal cell carcinoma metastases occurring subsequent to initial curative nephrectomy: an institutional review. Ann Surg Oncol 1994; 1:345-352.
19. Piltz S, Meimarakis G, Wichmann MW, et al. Long-term results after pulmonary resection of renal cell carcinoma metastases. Ann Thorac Surg 2002; 73:1082-1087.
20. Reddy S, Wolfgang CL. The role of surgery in the management of isolated metastases to the pancreas. Lancet Oncol 2009; 10:287-293. This is the most comprehensive review of pancreatic metastasectomy with the majority of patients treated for renal cell carcinoma.
21. Eggener SE,Yossepowitch O, Pettus JA,SnyderME,Motzer RJ,Russo P.Renal cell carcinoma recurrence after nephrectomy for localized disease: predicting survival from time of recurrence. J Clin Oncol 2006; 24:3101-3106.
22. Blom JH, van Poppel H, Marechal JM, et al. Radical nephrectomy with and without lymph-node dissection: final results of European Organization for Research and Treatment of Cancer (EORTC) randomized phase 3 trial 30881. Eur Urol 2009; 55:28-34. This is the only randomized controlled trial that evaluates the benefit of routine lymphadenectomy for clinically localized renal cell carcinoma.
23. Blute ML, Leibovich BC, Cheville JC, et al. A protocol for performing extended lymph node dissection using primary tumor pathological features for patients treated with radical nephrectomy for clear cell renal cell carcinoma. J Urol 2004; 172:465-469.
24. Boorjian SA, Crispen PL, Lohse CM, et al. Surgical resection of isolated retroperitoneal lymph node recurrence of renal cell carcinoma following nephrectomy. J Urol 2008; 180:99-103.
25. Murthy SC, Kim K, Rice TW, et al. Can we predict long-term survival after pulmonary metastasectomy for renal cell carcinoma? Ann Thorac Surg 2005; 79:996-1003.
26. Friedel G, Hurtgen M, Penzenstadler M, et al. Resection of pulmonary metastases from renal cell carcinoma. Anticancer Res 1999; 19 (2C):1593-1596.
27. Pfannschmidt J, Hoffmann H, Muley T, et al. Prognostic factors for survival after pulmonary resection of metastatic renal cell carcinoma. Ann Thorac Surg 2002; 74:1653-1657.
28. Cerfolio RJ, Allen MS, Deschamps C, et al. Pulmonary resection of metastatic renal cell carcinoma. Ann Thorac Surg 1994; 57:339-344.
29. Hofmann HS, Neef H, Krohe K, et al. Prognostic factors and survival after pulmonary resection of metastatic renal cell carcinoma. Eur Urol 2005; 48:77-81; discussion 81-172
30. Jackson RJ, Loh SC, Gokaslan ZL. Metastatic renal cell carcinoma of the spine: surgical treatment and results. J Neurosurg 2001; 94 (1 Suppl):18-24.
31. Kollender Y, Bickels J, Price WM, et al. Metastatic renal cell carcinoma of bone: indications and technique of surgical intervention. J Urol 2000; 164:1505-1508.
32. Adiga GU, Dutcher JP, Larkin M, et al. Characterization of bone metastases in patients with renal cell cancer. BJU Int 2004; 93:1237-1240.
33. Lin PP, Mirza AN, Lewis VO, et al. Patient survival after surgery for osseous metastases from renal cell carcinoma. J Bone Joint Surg Am 2007; 89:1794-1801.
34. Jung ST, Ghert MA, Harrelson JM, Scully SP. Treatment of osseous metastases in patients with renal cell carcinoma. Clin Orthop Relat Res 2003; 409:223-231.
35. Alves A, Adam R, Majno P, et al. Hepatic resection for metastatic renal tumors: is it worthwhile? Ann Surg Oncol 2003; 10:705-710.
36. Stief CG, Jahne J, Hagemann JH, et al. Surgery for metachronous solitary liver metastases of renal cell carcinoma. J Urol 1997; 158:375-377.
37. O'Rourke TR, Tekkis P, Yeung S, et al. Long-term results of liver resection for noncolorectal, nonneuroendocrine metastases. Ann Surg Oncol 2008; 15:207-218.
38. Shuch B, La Rochelle JC, Klatte T, et al. Brain metastasis from renal cell carcinoma: presentation, recurrence, and survival. Cancer 2008; 113:1641-1648.
39. Wronski M, Arbit E, Russo P, Galicich JH. Surgical resection of brain metastases from renal cell carcinoma in 50 patients. Urology 1996; 47:187-193.
40. Nieder C, Spanne O, Nordoy T, Dalhaug A. Treatment of brain metastases from renal cell cancer. Urol Oncol 2009. [Epub ahead of print]
41. Antonelli A, Cozzoli A, Simeone C, et al. Surgical treatment of adrenal metastasis from renal cell carcinoma: a single-centre experience of 45 patients. BJU Int 2006; 97:505-508.
42. Kim SH, Brennan MF, Russo P, et al. The role of surgery in the treatment of clinically isolated adrenal metastasis. Cancer 1998; 82:389-394.
43. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356:115-124.
44. Shuch B, Riggs SB, LaRochelle JC, et al. Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm. BJU Int 2008; 102:692-696. An interesting article that explores potential uses of molecular targeted therapy prior to surgical resection.
45. Cowey CL, Amin C, Pruthi RS, et al. Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma. J Clin Oncol 2010; 28:1502-1507. This is the first prospective trial to evaluate effectiveness and safety of neoadjuvant sorafenib.
46. Thomas AA, Rini BI, Lane BR, et al. Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. J Urol 2009; 181:518-523; discussion 523. An excellent observational study evaluating the response and adverse events associated with sunitinib prior to surgery.
47. van der Veldt AA, Meijerink MR, van den Eertwegh AJ, et al. Sunitinib for treatment of advanced renal cell cancer: primary tumor response. Clin Cancer Res 2008; 14:2431-2436.